To Compare Treatment With Doxorubicin or Capecitabine for Metastatic Breast Cancer in Women 60 Years and Older
Status: TERMINATED
Study type: INTERVENTIONAL
Conditions: Metastatic Breast Cancer
Interventions: DRUG: Pegylated liposomal doxorubicin|DRUG: Capecitabine
Sponsor: Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Collaborators: Tibotec Therapeutics, a Division of Ortho Biotech Products, L.P., USA